181 related articles for article (PubMed ID: 24731702)
1. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.
Hashim YM; Spitzer D; Vangveravong S; Hornick MC; Garg G; Hornick JR; Goedegebuure P; Mach RH; Hawkins WG
Mol Oncol; 2014 Jul; 8(5):956-67. PubMed ID: 24731702
[TBL] [Abstract][Full Text] [Related]
2. Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer.
Garg G; Vangveravong S; Zeng C; Collins L; Hornick M; Hashim Y; Piwnica-Worms D; Powell MA; Mutch DG; Mach RH; Hawkins WG; Spitzer D
Mol Cancer; 2014 Mar; 13():50. PubMed ID: 24602489
[TBL] [Abstract][Full Text] [Related]
3. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
[TBL] [Abstract][Full Text] [Related]
4. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.
Kashiwagi H; McDunn JE; Simon PO; Goedegebuure PS; Xu J; Jones L; Chang K; Johnston F; Trinkaus K; Hotchkiss RS; Mach RH; Hawkins WG
Mol Cancer; 2007 Jul; 6():48. PubMed ID: 17631687
[TBL] [Abstract][Full Text] [Related]
5. The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
Binder PS; Hashim YM; Cripe J; Buchanan T; Zamorano A; Vangveravong S; Mutch DG; Hawkins WG; Powell MA; Spitzer D
BMC Cancer; 2022 Mar; 22(1):263. PubMed ID: 35279106
[TBL] [Abstract][Full Text] [Related]
6. Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer.
Zeng C; Vangveravong S; McDunn JE; Hawkins WG; Mach RH
Br J Cancer; 2013 Oct; 109(9):2368-77. PubMed ID: 24104966
[TBL] [Abstract][Full Text] [Related]
7. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer.
Hornick JR; Vangveravong S; Spitzer D; Abate C; Berardi F; Goedegebuure P; Mach RH; Hawkins WG
J Exp Clin Cancer Res; 2012 May; 31(1):41. PubMed ID: 22551149
[TBL] [Abstract][Full Text] [Related]
8. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.
Ohman KA; Hashim YM; Vangveravong S; Nywening TM; Cullinan DR; Goedegebuure SP; Liu J; Van Tine BA; Tiriac H; Tuveson DA; DeNardo DG; Spitzer D; Mach RH; Hawkins WG
Oncotarget; 2016 Jun; 7(23):33529-41. PubMed ID: 27244881
[TBL] [Abstract][Full Text] [Related]
9. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.
Hornick JR; Xu J; Vangveravong S; Tu Z; Mitchem JB; Spitzer D; Goedegebuure P; Mach RH; Hawkins WG
Mol Cancer; 2010 Nov; 9():298. PubMed ID: 21092190
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.
Hornick JR; Spitzer D; Goedegebuure P; Mach RH; Hawkins WG
Surgery; 2012 Sep; 152(3 Suppl 1):S152-6. PubMed ID: 22763259
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis.
Yang C; Ran Q; Zhou Y; Liu S; Zhao C; Yu X; Zhu F; Ji Y; Du Q; Yang T; Zhang W; He S
Apoptosis; 2020 Jun; 25(5-6):441-455. PubMed ID: 32418059
[TBL] [Abstract][Full Text] [Related]
12. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma.
Kashiwagi H; McDunn JE; Simon PO; Goedegebuure PS; Vangveravong S; Chang K; Hotchkiss RS; Mach RH; Hawkins WG
J Transl Med; 2009 Mar; 7():24. PubMed ID: 19323815
[TBL] [Abstract][Full Text] [Related]
13. Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer.
Pati ML; Hornick JR; Niso M; Berardi F; Spitzer D; Abate C; Hawkins W
BMC Cancer; 2017 Jan; 17(1):51. PubMed ID: 28086830
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor activities in pancreatic cancer models.
Niso M; Kopecka J; Abatematteo FS; Berardi F; Riganti C; Abate C
Cell Oncol (Dordr); 2021 Dec; 44(6):1307-1323. PubMed ID: 34586588
[TBL] [Abstract][Full Text] [Related]
15. SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation.
Ludwig JM; Gai Y; Sun L; Xiang G; Zeng D; Kim HS
Mol Oncol; 2016 Aug; 10(7):1133-45. PubMed ID: 27262893
[TBL] [Abstract][Full Text] [Related]
16. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
17. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling.
Spitzer D; Simon PO; Kashiwagi H; Xu J; Zeng C; Vangveravong S; Zhou D; Chang K; McDunn JE; Hornick JR; Goedegebuure P; Hotchkiss RS; Mach RH; Hawkins WG
Cancer Res; 2012 Jan; 72(1):201-9. PubMed ID: 22065721
[TBL] [Abstract][Full Text] [Related]
18. The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer.
Hagi T; Vangveravong S; Takchi R; Gong Q; Goedegebuure SP; Tiriac H; Van Tine BA; Powell MA; Hawkins WG; Spitzer D
Sci Rep; 2024 Mar; 14(1):6373. PubMed ID: 38493257
[TBL] [Abstract][Full Text] [Related]
19. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
[TBL] [Abstract][Full Text] [Related]
20. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
